AR131560A1 - Métodos para tratar pots mediante el uso de antagonistas de fcrn - Google Patents
Métodos para tratar pots mediante el uso de antagonistas de fcrnInfo
- Publication number
- AR131560A1 AR131560A1 ARP240100028A ARP240100028A AR131560A1 AR 131560 A1 AR131560 A1 AR 131560A1 AR P240100028 A ARP240100028 A AR P240100028A AR P240100028 A ARP240100028 A AR P240100028A AR 131560 A1 AR131560 A1 AR 131560A1
- Authority
- AR
- Argentina
- Prior art keywords
- pots
- treating
- fcrn
- methods
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente descripción se proporcionan métodos para tratar el síndrome de taquicardia ortostática postural (POTS) mediante el uso de una cantidad eficaz de un antagonista del receptor de Fc neonatal (FcRn) humano. En la presente descripción también se proporcionan antagonistas de FcRn para su uso en el tratamiento de POTS y para su uso en la fabricación de un medicamento para el tratamiento de POTS. Reivindicación 1: Un método para tratar el síndrome de taquicardia ortostática postural (POTS) en un sujeto que lo necesita, el método comprende administrar al sujeto una cantidad eficaz de un antagonista del receptor de Fc neonatal (FcRn) humano. Reivindicación 55: Un antagonista de FcRn para su uso en el tratamiento de POTS, en donde el tratamiento se realiza de acuerdo con el método de cualquiera de las reivindicaciones 1 - 54. Reivindicación 56: Un antagonista de FcRn para su uso en la fabricación de un medicamento para el tratamiento de POTS, en donde el tratamiento se realiza de acuerdo con el método de cualquiera de las reivindicaciones 1 - 54.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363437552P | 2023-01-06 | 2023-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR131560A1 true AR131560A1 (es) | 2025-04-09 |
Family
ID=89983623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100028A AR131560A1 (es) | 2023-01-06 | 2024-01-05 | Métodos para tratar pots mediante el uso de antagonistas de fcrn |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR131560A1 (es) |
| TW (1) | TW202432178A (es) |
| WO (1) | WO2024147074A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020005981A (es) | 2017-12-08 | 2020-08-24 | Argenx Bvba | Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada. |
| MY209122A (en) | 2018-06-08 | 2025-06-23 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| DK4087875T3 (da) | 2020-01-08 | 2024-10-28 | argenx BV | Antagonister af human neonatal Fc-receptor (FcRn) til behandling af pemphigus-sygdomme |
| JP2025520431A (ja) | 2022-06-15 | 2025-07-03 | アルジェニクス ビーブイ | Ｆｃｒｎ／抗原結合分子及び使用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20090252729A1 (en) | 2007-05-14 | 2009-10-08 | Farrington Graham K | Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto |
| IL320058A (en) * | 2016-07-29 | 2025-06-01 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| MX2020005981A (es) | 2017-12-08 | 2020-08-24 | Argenx Bvba | Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada. |
| WO2021022249A1 (en) * | 2019-08-01 | 2021-02-04 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
-
2024
- 2024-01-05 TW TW113100585A patent/TW202432178A/zh unknown
- 2024-01-05 WO PCT/IB2024/000018 patent/WO2024147074A1/en not_active Ceased
- 2024-01-05 AR ARP240100028A patent/AR131560A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024147074A1 (en) | 2024-07-11 |
| TW202432178A (zh) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR131560A1 (es) | Métodos para tratar pots mediante el uso de antagonistas de fcrn | |
| AR131601A1 (es) | MÉTODOS PARA TRATAR EL SÍNDROME DE SJÖGREN PRIMARIO MEDIANTE EL USO DE ANTAGONISTAS DE FcRn | |
| AR130995A1 (es) | Métodos para el tratamiento de nefropatías membranosas primarias mediante el uso de antagonistas de fcrn | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| MX2021002556A (es) | Tratamiento del dolor postquirurgico. | |
| MX2024013015A (es) | Métodos para tratar penfigoide ampolloso con el uso de antagonistas de fcrn | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| ECSP22089498A (es) | Inhibidores de il4i1 y métodos de uso | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| MX2021004207A (es) | Uso de reboxetina para el tratamiento de narcolepsia. | |
| MX2025005378A (es) | Metodos para el tratamiento de enfermedades cardiovasculares | |
| CL2024002627A1 (es) | Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor. | |
| MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. | |
| Albagieh et al. | Efficacy of lidocaine versus mepivacaine in the management of myofascial pain | |
| Velázquez-Delgado et al. | Postoperative analgesia with dexmedetomidine in interscalene block. Comparative study | |
| Singh | Autologous blood versus corticosteroid local injection for treatment of lateral epicondylosis: a randomized clinical trial | |
| Aufiero et al. | Treatment of medial and lateral elbow tendinosis with an injectable amniotic membrane allograft: a retrospective case series | |
| CL2022000496A1 (es) | Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátrico | |
| Özdemir et al. | The effect of steroid injection by Novel method in carpal tunnel syndrome on pain severity and electrophysiological findings. | |
| EA202000298A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ | |
| AR128568A1 (es) | Métodos para tratar la miositis mediante el uso de antagonistas de fcrn | |
| Kayatha et al. | Treatment outcome of tennis elbow by percutaneous needle tenotomy | |
| CHOWDARY | EVALUATION OF USEFULNESS OF LASER THERAPY IN MANAGEMENT OF DIABETIC FOOT ULCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |